Towards graft-specific immune suppression: Gene therapy of the transplanted kidney

Maria Sandovici, Leo E. Deelman, Ariela Benigni, Robert H. Henning

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Kidney transplantation remains the best therapeutic option for patients with end-stage renal disease. Immunosuppressive therapy has largely resolved the issue of acute transplant rejection. However, because of its systemic nature, immunosuppressive therapy trades off efficacy against side-effects and its chronic use has been associated with severe infections and malignancy. Moreover, long-term survival of renal grafts did not change over the past twenty years. This situation may be improved by using gene therapy as an alternative or add-on strategy to the classic, systemic immune suppression. This review discusses gene therapy approaches in kidney transplantation by addressing the essentials of delivery vectors and by outlining strategies to achieve local immunosupression and allograft-specific tolerance, both in acute rejection and chronic transplant dysfunction. Employing such strategies, local suppression of the immune response and induction of transplantation-specific tolerance have been accomplished in experimental gene therapy. If successful in the clinical setting, gene therapy may (partially) substitute systemic, non-selective immunosuppressive medication, with a major impact on the quality of life and survival of the transplanted patients as well as on the waiting time for receiving a renal graft.

Original languageEnglish
Pages (from-to)1358-1368
Number of pages11
JournalAdvanced Drug Delivery Reviews
Volume62
Issue number14
DOIs
Publication statusPublished - Nov 30 2010

Fingerprint

Genetic Therapy
Immunosuppressive Agents
Transplantation Tolerance
Transplants
Kidney
Graft Rejection
Kidney Transplantation
Investigational Therapies
Graft Survival
Chronic Kidney Failure
Therapeutics
Quality of Life
Survival
Infection
Neoplasms

Keywords

  • Gene delivery
  • Kidney transplantation
  • Liposome
  • Plasmid
  • Rejection
  • Small interfering RNA
  • Tolerance
  • Virus

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Towards graft-specific immune suppression : Gene therapy of the transplanted kidney. / Sandovici, Maria; Deelman, Leo E.; Benigni, Ariela; Henning, Robert H.

In: Advanced Drug Delivery Reviews, Vol. 62, No. 14, 30.11.2010, p. 1358-1368.

Research output: Contribution to journalArticle

Sandovici, Maria ; Deelman, Leo E. ; Benigni, Ariela ; Henning, Robert H. / Towards graft-specific immune suppression : Gene therapy of the transplanted kidney. In: Advanced Drug Delivery Reviews. 2010 ; Vol. 62, No. 14. pp. 1358-1368.
@article{7ec7fb00eaff40e99858a4bda77842d3,
title = "Towards graft-specific immune suppression: Gene therapy of the transplanted kidney",
abstract = "Kidney transplantation remains the best therapeutic option for patients with end-stage renal disease. Immunosuppressive therapy has largely resolved the issue of acute transplant rejection. However, because of its systemic nature, immunosuppressive therapy trades off efficacy against side-effects and its chronic use has been associated with severe infections and malignancy. Moreover, long-term survival of renal grafts did not change over the past twenty years. This situation may be improved by using gene therapy as an alternative or add-on strategy to the classic, systemic immune suppression. This review discusses gene therapy approaches in kidney transplantation by addressing the essentials of delivery vectors and by outlining strategies to achieve local immunosupression and allograft-specific tolerance, both in acute rejection and chronic transplant dysfunction. Employing such strategies, local suppression of the immune response and induction of transplantation-specific tolerance have been accomplished in experimental gene therapy. If successful in the clinical setting, gene therapy may (partially) substitute systemic, non-selective immunosuppressive medication, with a major impact on the quality of life and survival of the transplanted patients as well as on the waiting time for receiving a renal graft.",
keywords = "Gene delivery, Kidney transplantation, Liposome, Plasmid, Rejection, Small interfering RNA, Tolerance, Virus",
author = "Maria Sandovici and Deelman, {Leo E.} and Ariela Benigni and Henning, {Robert H.}",
year = "2010",
month = "11",
day = "30",
doi = "10.1016/j.addr.2010.07.010",
language = "English",
volume = "62",
pages = "1358--1368",
journal = "Advanced Drug Delivery Reviews",
issn = "0169-409X",
publisher = "Elsevier",
number = "14",

}

TY - JOUR

T1 - Towards graft-specific immune suppression

T2 - Gene therapy of the transplanted kidney

AU - Sandovici, Maria

AU - Deelman, Leo E.

AU - Benigni, Ariela

AU - Henning, Robert H.

PY - 2010/11/30

Y1 - 2010/11/30

N2 - Kidney transplantation remains the best therapeutic option for patients with end-stage renal disease. Immunosuppressive therapy has largely resolved the issue of acute transplant rejection. However, because of its systemic nature, immunosuppressive therapy trades off efficacy against side-effects and its chronic use has been associated with severe infections and malignancy. Moreover, long-term survival of renal grafts did not change over the past twenty years. This situation may be improved by using gene therapy as an alternative or add-on strategy to the classic, systemic immune suppression. This review discusses gene therapy approaches in kidney transplantation by addressing the essentials of delivery vectors and by outlining strategies to achieve local immunosupression and allograft-specific tolerance, both in acute rejection and chronic transplant dysfunction. Employing such strategies, local suppression of the immune response and induction of transplantation-specific tolerance have been accomplished in experimental gene therapy. If successful in the clinical setting, gene therapy may (partially) substitute systemic, non-selective immunosuppressive medication, with a major impact on the quality of life and survival of the transplanted patients as well as on the waiting time for receiving a renal graft.

AB - Kidney transplantation remains the best therapeutic option for patients with end-stage renal disease. Immunosuppressive therapy has largely resolved the issue of acute transplant rejection. However, because of its systemic nature, immunosuppressive therapy trades off efficacy against side-effects and its chronic use has been associated with severe infections and malignancy. Moreover, long-term survival of renal grafts did not change over the past twenty years. This situation may be improved by using gene therapy as an alternative or add-on strategy to the classic, systemic immune suppression. This review discusses gene therapy approaches in kidney transplantation by addressing the essentials of delivery vectors and by outlining strategies to achieve local immunosupression and allograft-specific tolerance, both in acute rejection and chronic transplant dysfunction. Employing such strategies, local suppression of the immune response and induction of transplantation-specific tolerance have been accomplished in experimental gene therapy. If successful in the clinical setting, gene therapy may (partially) substitute systemic, non-selective immunosuppressive medication, with a major impact on the quality of life and survival of the transplanted patients as well as on the waiting time for receiving a renal graft.

KW - Gene delivery

KW - Kidney transplantation

KW - Liposome

KW - Plasmid

KW - Rejection

KW - Small interfering RNA

KW - Tolerance

KW - Virus

UR - http://www.scopus.com/inward/record.url?scp=78649445784&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78649445784&partnerID=8YFLogxK

U2 - 10.1016/j.addr.2010.07.010

DO - 10.1016/j.addr.2010.07.010

M3 - Article

C2 - 20688115

AN - SCOPUS:78649445784

VL - 62

SP - 1358

EP - 1368

JO - Advanced Drug Delivery Reviews

JF - Advanced Drug Delivery Reviews

SN - 0169-409X

IS - 14

ER -